alexa HER2-Neu Gene Testing in Gastric Cancer by Immunohistochemistry in Tunisian Patient’s Samples | OMICS International| Abstract
ISSN: 2476-2253

Journal of Cancer Diagnosis
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Review Article   
  • J Cancer Diagn 2017, Vol 2(1): 110
  • DOI: 10.4172/2476-2253.1000110

HER2-Neu Gene Testing in Gastric Cancer by Immunohistochemistry in Tunisian Patient’s Samples

Tarek Gharsalli1*, Habib Bouazzi2, Bashair Aiwasiyah3, Mahassen Sassi4 and Badreddine Sriha4,5
1Pharmacy Faculty of Monastir, , Tunisia
2Hôpital Necker-Enfants Malades, Medical Genetics Laboratory, Paris Descartes University, France
3King Abdulaziz University Hospital, Jeddah, Saudi Arabia
4Medicine Faculty of Sousse, , Tunisia
5Laboratory of Anatomy and Pathological Cytology, Hospital Farhat Hached of Sousse, , Tunisia
*Corresponding Author : Tarek Gharsalli, Pharmacy Faculty of Monastir, Monastir, Tunisia, Tel: +21677473777, Email: [email protected]

Received Date: Nov 07, 2016 / Accepted Date: Feb 21, 2017 / Published Date: Feb 27, 2017


Immunohistochemical (IHC) testing for HER2/neu is becoming the standard of care for guiding the adjuvant treatment of gastric carcinoma with trastuzumab. Up to now, gastric cancer has been considered the most commonly diagnosed tumors leading to death. In this study, we evaluate the detection of HER2 expression by IHC in Tunisian patients with gastric cancer according to the international consensus. A total of 84 tumor specimens was assessed for HER2 expression by immunohistochemistry (IHC) using the antibodies HercepTest™. Doubtful IHC results (IHC 2+) were resolved by HER2 Chromogenic in situ hybridization (CISH). Thus, 10.5% of samples were HER2-positive (3+), 8.3% having a negative score IHC, Her2-Neu (+1) and 3.6% to be a dubious immunostaining Her2-Neu (2+).

Keywords: HER2-Neu Gene; Gastric cancer; Trastazumab; Immunohistochemistry; In Situ Hybridization

Citation: Gharsalli T, Bouazzi H, Aiwasiyah B, Sassi M, Sriha B (2017) HER2-Neu Gene Testing in Gastric Cancer by Immunohistochemistry in Tunisian Patient’s Samples. J Cancer Diagn 2: 110. Doi: 10.4172/2476-2253.1000110

Copyright: © 2017 Gharsalli T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Recommended Conferences
Article Usage
  • Total views: 3293
  • [From(publication date): 0-2017 - Jun 05, 2020]
  • Breakdown by view type
  • HTML page views: 3103
  • PDF downloads: 190